SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC TLC TWO: 4152))) today announced that the management team is scheduled to present at the two upcoming investor conferences:
Baird Global Healthcare Conference
Dates: Wednesday - Thursday, September 4-5, 2019
Presentation: 10:15am ET, Thursday, September 5, 2019
Location: InterContinental New York Barclay, New York
Janney Montgomery Scott Healthcare Conference
Dates: Monday – Tuesday, September 9-10, 2019
Presentation: 9:55am ET, Tuesday, September 10, 2019
Location: The Union League Club, New York
The Company will also conduct one-on-one meetings. A copy of the TLC presentation can be accessed under "Events and Presentations" in the Investors section of TLC's website at www.tlcbio.com.
About TLC
TLC TLC TWO: 4152))) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC's BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan's Corporate Governance Evaluations.
Media Contact: Dawn Chi Corporate Communications +886 2 2655 7377 ext. 136 dawn@tlcbio.com Investor Contact: Xuan Yang Solebury Trout +1 646 378 2975 xyang@troutgroup.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.